ARKRAY USA

MINNEAPOLIS, June 17, 2016 (PR NEWSWIRE) – ARKRAY USA, Inc., a leader in diabetes care products, announced that Parkland Health & Hospital System of Dallas has selected ARKRAY’s GLUCOCARD Expression blood glucose monitoring system (BGMS) for use by Parkland’s out-patient diabetic population. The ability to accurately measure glucose levels in blood is essential for people afflicted with diabetes so they can effectively manage the disease, according to the American Diabetes Association (ADA).

The GLUCOCARD Expression is an audio-enabled BGMS with a large display and tactile buttons, ideally suited for patients with dexterity or visual impairment. Users have the option of hearing their testing results in English or Spanish.

“ARKRAY is proud that Parkland, one of the top public hospitals in the US, chose to entrust the health of their diabetic patients with the GLUCOCARD Expression,” said ARKRAY USA President Jonathan Chapman. “Parkland patients using GLUCOCARD Expression can expect to receive consistently accurate and reliable readings of their blood glucose levels, giving them the information they need to live a healthier and more fulfilling life.”

Diabetes, or diabetes mellitus, is a metabolic type of disease in which affected people have high blood glucose (blood sugar), either because insulin production is inadequate (Type 2), or because the islet cells in the pancreas no longer produce insulin (Type 1, sometimes referred to as juvenile diabetes). The ADA estimates that more than 30 million Americans suffer from either Type 1 or Type 2 diabetes and that 25.9% of American’s 65 years of age or greater will have diabetes.

###

About Parkland Health & Hospital System

Parkland has consistently been recognized as one of the top public hospitals in the United States. In 2015, The Leapfrog Group named Parkland to its annual list of Top Hospitals. Parkland was one of only 98 Top Hospitals recognized in the U.S. based on the results of The Leapfrog Group’s annual hospital survey, which measures hospitals’ performance on patient safety and quality.

About ARKRAY USA, Inc.

ARKRAY USA, Inc. is a division of ARKRAY, a global leader in diabetes care with headquarters in Kyoto, Japan. For more than half a century, ARKRAY has pioneered products to ensure that people who have diabetes - and the health professionals who care for them - can better manage the condition. ARKRAY currently does business in more than 80 countries worldwide and is the market leader in diabetes management in the long-term care market in the U.S. The Company has a long history of developing cutting edge technology such as the first portable glucose analyzer available in the United States; the first HbA1C analyzer; and the first hand-held blood glucose meter. For more information, visit www.arkrayusa.com.